Several health care company executives and lobbyists who quietly met with federal government policymakers a couple months ago secured favorable policies in Medicare's latest payment rules. Clinical laboratories, outpatient heart labs and a bladder cancer drug each won particular measures.
Why it matters: Medicare's annual payment rules are buried in bureaucratic and complex language. But that's where a lot of policy action is, and companies spend a lot of time and money influencing the process, often to get higher Medicare payouts. The 2018 proposals are no different.